NCT05238831 2024-01-23SMMART Adaptive Clinical Treatment (ACT) TrialOHSU Knight Cancer InstitutePhase EARLY_PHASE1 Withdrawn
NCT01875666 2020-09-04Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + LapatinibUNC Lineberger Comprehensive Cancer CenterPhase EARLY_PHASE1 Completed26 enrolled